The DOI matches its Crossref record.
Zopiclone and Triazolam in Insomnia Associated with Generalized Anxiety Disorder: a Placebo-controlled Evaluation of Efficacy and Daytime Anxiety
Abstract
In a double-blind placebo-controlled study, following a 1 week washout, 75 outpatients suffering from generalized anxiety disorder with severe insomnia as the target symptom were randomly assigned to 4 weeks of treatment with zopiclone 7.5 mg, triazolam 0.5 mg or placebo at bedtime. Zopiclone was significantly better than placebo on most sleep parameters. Triazolam tended to be superior to placebo, but its superiority was significant only on the sleep induction factor. Triazolam-treated patients presented significantly more day-time-interdose anxiety than zopiclone as assessed by the weekly HARS and Clinical Global Assessment of Anxiety. Although daytime-interdose anxiety was observed with both drugs, this treatment emergent symptom was more frequent and severe with triazolam. Side-effects were of a mild to moderate intensity for both zopiclone and triazolam; however, taste perversion frequently appeared with zopiclone. Although both drugs share similar pharmacological properties and bind to benzodiazepine receptors, they differ significantly with respect to side-effects and daytime anxiety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Eszopiclone cessation produced new withdrawal symptoms (abnormal dreams, nausea, upset stomach) and rebound anxiety.
“(1) one report of eszopiclone cessation produced new withdrawal symptoms (i.e., abnormal dreams, nausea, upset stomach) and rebound anxiety [31]”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [31]
Citations
Cited by
Sorted by citations
Meta-analysis of benzodiazepine use in the treatment of insomnia.
(2000) · PubMed Central · Cited by 613
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
“Daytime withdrawal symptoms may occur and have been described with triazolam and zopiclone [117,118].”
BackgroundBenzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationNoble, S., Langtry, H. D., & Lamb, H. M. (1998) · Drugs · doi:10.2165/00003495-199855020-00015 · Cited by 255
“was superior to placebo only for sleep induction time.[31]”
InfluentialA Comparative Assessment of the Risks and Benefits of Zopiclone
Hajak, G. (1999) · Drug Safety · doi:10.2165/00002018-199921060-00003 · Cited by 213
Mellman, T. A. (2008) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2008.01.010 · Cited by 204
Mellman, T. A. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.08.005 · Cited by 165
Pollack, M. H., Kinrys, G., Krystal, A. D., McCall, W. V., Roth, T. G., Schaefer, K., Rubens, R., Roach, J. M., Huang, H., & Krishnan, R. R. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.551 · Cited by 158
Mott, A. E., & Leopold, D. A. (1991) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30391-1 · Cited by 157
A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
Mitte, K., Noack, P., Steil, R., & Hautzinger, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155821.74832.f9 · Cited by 137
Chavant, F., Favrelière, S., Lafay‐Chebassier, C., Plazanet, C., & Pérault‐Pochat, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04009.x · Cited by 92
DIAGNOSIS AND MANAGEMENT OF TASTE DISORDERS AND BURNING MOUTH SYNDROME
Mott, A. E., Grushka, M., & Sessle, B. J. (1993) · Dental Clinics of North America · doi:10.1016/s0011-8532(22)00289-0 · Cited by 93
Eating Disorders, Addictions and Substance Use Disorders
Brewerton, T. D., & Baker Dennis, A. (2014) · Springer eBooks · doi:10.1007/978-3-642-45378-6 · Cited by 87
Wadworth, A. N., & McTavish, D. (1993) · Drugs & Aging · doi:10.2165/00002512-199303050-00006 · Cited by 79
Zopiclone: Is there any dependence and abuse potential?
LADER, M. H. (1997) · Journal of Neurology · doi:10.1007/bf03160567 · Cited by 53
Liebrenz, M., Gehring, M.-T., Buadze, A., & Caflisch, C. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0493-y · Cited by 40
“Benzodiazepine withdrawal syndrome has been reported following attempts to withdraw even from low or therapeutic doses [12,17], and has been compared to barbiturate and alcohol withdrawal [18-20].”
ResultClinical Pharmacology of Sleep
Pandi-Perumal, S. R., & Monti, J. M. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7440-3 · Cited by 31
Withdrawal Reactions after Stopping Hypnotics in Patients with Insomnia
LADER, M. H. (1998) · CNS Drugs · doi:10.2165/00023210-199810060-00004 · Cited by 32
Psychiatric Comorbidity: The Case for Treating Insomnia
Krystal, A. D. (2006) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2006.06.007 · Cited by 17
“One study randomly assigned 75 patients who had GAD associated with insomnia to 4 weeks of nightly treatment with zopiclone (7.5 mg), triazolam (0.5 mg), or placebo [ 28 ].”
MethodInfluentialEndicott, J., Svedsäter, & Locklear (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s32320 · Cited by 16
“Neuropsychiatric Disease and Treatment 2012:8 significant improvements in sleep quality reported with selective serotonin reuptake inhibitors, cyclopyrrolones, and benzodiazepines.(37,38) Our analyses of PSQI scores in the acute and maintenance studies confirm that quetiapine XR is significantly more effective in impr…”
Clinical pharmacology and therapeutics
Horton, R. C., & Kendall, M. J. (1991) · Postgraduate Medical Journal · doi:10.1136/pgmj.67.794.1042 · Cited by 16
Bouklouze, A., Viré, J. ‐., Quarin, G., et al. (1994) · Electroanalysis · doi:10.1002/elan.1140061122 · Cited by 15
Oswald, I. (1991) · The Lancet · doi:10.1016/0140-6736(91)90592-d · Cited by 10
Rebound and withdrawal with benzodiazepine and non-benzodiazepine hypnotic medication
LADER, M. H. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_15 · Cited by 10
Hajak, G., Clarenbach, P., Fischer, W., Haase, W., Bandelow, B., Adler, L., & Rüther, E. (1995) · European Psychiatry · doi:10.1016/0924-9338(96)80100-3 · Cited by 7
“…numbers of insomniacs, in which 7.5 mg zopiclone was compared with 0.25 mg or 0.5 mg triazolam (Steinert er al, 1984; Venter et al, 1986; Autret et al, 1987; Chaudoir et al, 1990; Elie et al, 1990; Fleming et al, 1990; Fontaine et al, 1990; Mouret et al, 1990) or 1 mg flunitrazepam (Lassen, 1991).”
MethodInfluentialUhde, T. W., & Cortese, B. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-74753-8_5 · Cited by 8
Anxiety Disorders and Posttraumatic Stress Disorder
Krystal, A. D., Stein, M. B., & Szabo, S. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00136-7 · Cited by 9
Efficacy and Safety of Zopiclone and Eszopiclone in the Treatment of Primary and Comorbid Insomnia
Najib, J. S. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_18 · Cited by 9
“Results of a study in subjects with GAD [76] noted that administration of zopiclone 7.”
BackgroundAlfano, C. A., & Mellman, T. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777493.019 · Cited by 6
Introduction to Substance Use Disorders for the Eating Disorder Specialist
Dennis, A. B., & Pryor, T. L. (2014) · Springer eBooks · doi:10.1007/978-3-642-45378-6_12 · Cited by 3
Pharmacological management of psychoactive substance withdrawal syndrome
Fluyau, D., Cook, S., Chima, A., Kailasam, V. K., & Revadigar, N. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00874-7 · Cited by 2
The Science and Art of Prescribing for Insomnia
Wilson, S. J., & Selsick, H. (2018) · Springer eBooks · doi:10.1007/978-3-642-54836-9_8
Guille, C., Cortese, B. M., & Uhde, T. W. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1703-7.10055-6
Therapeutic and adverse drug effects
Mollayeva, T., & Shapiro, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00023-2 · Cited by 1
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt076
Pian, K. L. H., & Nederstigt, M. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2524-5_12
Metadata
- Authors
- FONTAINE, R., BEAUDRY, P., MORVAN, P. L., BEAUCLAIR, L., & CHOUINARD, G.
- Affiliations
- Royal Victoria Hospital (CA)
- ORCID
- BEAUCLAIR, LINDA
- Venue
- International Clinical Psychopharmacology
- Published
- 1990-07
- Volume
- 5
- Issue
- 3
- Pages
- 173-184
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2054991742
- Cited by
- 37
- References
- 0
- Citations by year
- 2021: 2 · 2020: 2 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 2 · 2012: 2
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Keywords
- zopiclone, triazolam, insomnia, generalized anxiety disorder, benzodiazepines, sleep induction, adverse effects, sleep quality
- MeSH terms
- Adult, Anxiety Disorders, Drug Administration Schedule, Female, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Piperazines, Psychiatric Status Rating Scales, Sleep, Triazolam, Azabicyclo Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
